GH secretagogues
Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children
Thorner M, Rochiccioli P, Colle M, et al. · J Clin Endocrinol Metab · 1990
PMID: 2140733 · DOI: 10.1210/jcem-71-2-470
Summary
12-month clinical study of continuous subcutaneous GHRH(1-29)NH2 (sermorelin) in short, slowly growing children. Endpoints: height velocity, IGF-I response.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →Sermorelin29-residue GHRH analog. Studied as a research probe of the somatotropic axis.
Guides covering this compound
More GH secretagogues citations
- Ipamorelin, the first selective growth hormone secretagogueEur J Endocrinol · 1998
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in ratsGrowth Horm IGF Res · 1999
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsJ Clin Endocrinol Metab · 2006